Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (08) : 756-759     DOI: 10.3971/j.issn.1000-8578.2022.22.0106
|
Exploration of Peritoneal Metastasis of Advanced Ovarian Cancer and Maintenance Treatment with Traditional Chinese Medicine Based on Theory of Membranous Sanjiao
LU Wenping
Department of Oncology, Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100053, China
Download: PDF(3836 KB)   ( 42 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Ovarian cancer has the highest mortality among the three major gynecological malignancies. Peritoneal metastasis, intestinal obstruction and then death is the main outcome pattern of advanced ovarian cancer. Traditional Chinese medicine maintenance treatment of advanced ovarian cancer is effective, but the theoretical basis needs to be further improved. Under the guidance of the membranous Sanjiao theory and combined with clinical experience, this paper traces the origin, focuses the location of membranous Sanjiao of ovarian cancer peritoneal metastasis and the role of membranous Sanjiao dysfunction in the occurrence and metastasis of ovarian cancer. Besides, the paper puts forward that the main strategies for the maintenance treatment of traditional Chinese medicine on ovarian cancer are ordering the Qi movement of Sanjiao, regulating and harmonizing Qi and blood, and clearing away the latent toxin. From the perspective of membranous Sanjiao theory, the theory enriches the traditional Chinese medicine theory of ovarian cancer and provides new ideas for the treatment of ovarian cancer.
Keywords Ovarian cancer      Peritoneal metastasis      Membranous Sanjiao      TCM maintenance therapy     
ZTFLH:  R737.31  
Issue Date: 11 August 2022
 Cite this article:   
LU Wenping. Exploration of Peritoneal Metastasis of Advanced Ovarian Cancer and Maintenance Treatment with Traditional Chinese Medicine Based on Theory of Membranous Sanjiao[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 756-759.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0106
http://www.zlfzyj.com/EN/Y2022/V49/I08/756
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
LU Wenping
[1] Wentzensen N, Poole EM, Trabert B, et al. Ovarian Cancer Risk
Factors by Histologic Subtype: An Analysis From the Ovarian
Cancer Cohort Consortium[J]. J Clin Oncol, 2016, 34(24):
2888-2898.
[2] Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian
cancer[J]. Lancet, 2019, 393(10177): 1240-1253.
[3] 张丽芬. 三焦之质、用、候、脉、病、方、药考[J]. 环球中
医药, 2020, 13(10): 1740-1742. [Zhang LF. The Inspection of
Triple Energizer in Essence, Utility, Syndrome, Pulse, Disease,
Prescription and Chinese Pharmacy[J]. Huan Qiu Zhong Yi Yao,
2020, 13(10): 1740-1742.]
[4] 张晓梅, 姜良铎, 肖培新. 三焦膜性管道[J]. 环球中医药,
2019, 12(7): 1054-1056. [Zhang XM, Jiang LD, Xiao PX. The
Membranous Channels of Triple Energizer[J]. Huan Qiu Zhong Yi
Yao, 2019, 12(7): 1054-1056.]
[5] 王永洲. “大三焦”有形结构辨识[J]. 中医药导报, 2021, 27(5): 9-12.
[Wang YZ. The Identify of “Generalized Triple Energizer” Tangible
Structures[J]. Zhong Yi Yao Dao Bao, 2021, 27(5): 9-12.]
[6] 刘舟, 张卫华, 陈刚. 论腠理与三焦的关系[J]. 四川中医, 2011,
29(12): 498-500. [Liu Z, Zhang WH, Chen G. A View on the
Relationship Between Couli and Sanjiao[J]. Sichuan Zhong Yi,
2011, 29(12): 498-500.]
[7] 邓怀涵. 陈潮祖教授“膜腠三焦”学术思想及临证运用研究
[D]. 成都: 成都中医药大学, 2019. [Deng HH. Professor Chen
Chaozu’s Academic Thought and Clinical Application of “Triple
Energizer composed by Membrane &Striae”[D]. Chengdu:
Chengdu University of Traditional Chinese Medicine, 2019.]
[8] 李洪海, 韩琦, 李萍, 等. 从膜谈三焦实质[J]. 中华中医药杂志,
2018, 33(7): 2846-2848. [Li HH, Han Q, Li P, et al. Discuccion on
the essence of sanjiao from the theory of membrane[J]. Zhonghua
Zhong Yi Yao Za Zhi, 2018, 33(7): 2846-2848.]
[9] 凌昌全. 癌毒是恶性肿瘤之根本[J]. 中西医结合学报, 2008, 6(2):
111-114. [Ling CQ. Cancerous toxin is the key pathogenic factor
of malignant tumor[J]. Zhong Xi Yi Jie He Xue Bao, 2008, 6(2):
111-114.]
[10] 周仲瑛, 李柳, 金路. 三焦“有名无形论”探析[J]. 江苏中医药,
2021, 53(1): 1-3. [Zhou ZY, Li L, Jin L. The Study on Sanjiao
“Famous Invisible Theory”[J]. Jiangsu Zhong Yi Yao, 2021,
53(1): 1-3.]
[11] 叶乃菁, 刘宣, 李琦. 癌毒转移的中医理论探讨[J]. 中医杂
志, 2014, 55(3): 185-188. [Ye NJ, Liu X, Li Q. TCM theory of
carcinomatous toxin metastasis[J]. Zhong Yi Za Zhi, 2014, 55(3):
185-188.]
[12] Etzerodt A, Moulin M, Doktor TK, et al. Tissue-resident
macrophages in omentum promote metastatic spread of ovarian
cancer[J]. J Exp Med, 2020, 217(4): e20191869.
[13] MaX. The omentum, a niche for premetastatic ovarian cancer[J]. J
Exp Med, 2020, 217(4): e20192312.
[14] Catalano V, Turdo A, Di Franco S, et al. Tumor and its
microenvironment: a synergistic interplay[J]. Semin Cancer Biol,
2013, 23(6 Pt B): 522-532.
[15] Lee W, Ko SY, Mohamed MS, et al. Neutrophils facilitate ovarian
cancer premetastatic niche formation in the omentum[J]. J Exp
Med, 2019, 216(1): 176-194.
[16] 李娟, 翁洁琼, 卢雯平. 益气活血解毒方治疗晚期上皮性卵巢
癌疗效相关靶基因筛选[J]. 中国中医药信息杂志, 2020, 27(4):
28-34. [Li J, Weng JQ, Lu WP. Screening of target genes related
to efficacy of YiqiHuoxueJiedu decoction for advanced epithelial
ovarian cancer[J]. Zhongguo Zhong Yi Yao Xin Xi Za Zhi, 2020,
27(4): 28-34.]
[17] Li YF, Li J, Fan BF, et al. Efficacy and safety of YiqiHuoxueJiedu
decoction for the treatment of advanced epithelial ovarian cancer
patients: a double-blind randomized controlled clinical trial[J]. J
Tradit Chin Med, 2020, 40(1): 103-111.
Related articles from Frontiers Journals
[1] GAO Haining, BAI Ruixia, ZHAO Pengwei, SONG Wanying, LIN Xuan. Effect of miR-581 on Autophagy of Ovarian Cancer SKOV3 Cells by Regulating FOXO1[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 403-407.
[2] HE Liya, CHEN Yaqing. Progress of Surgery on Platinum-sensitive Recurrent Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 903-906.
[3] WANG Hanyuan, ZHAO Zhiying, GONG Tingting, ZHAO Yuhong, WU Qijun. 王瀚苑,赵之滢,宫婷婷,赵玉虹,吴琪俊[J]. Cancer Research on Prevention and Treatment, 2021, 48(08): 804-808.
[4] LI Na, DAI Congwei, YANG Yanyan, WEI Qiang, QIU Gang, WU Xiaohua. Effect and Molecular Mechanism of MFG-E8 on Sensitivity of Ovarian Cancer SKOV3 Cells to Cisplatin[J]. Cancer Research on Prevention and Treatment, 2021, 48(05): 464-469.
[5] LI Haoran, WANG Yali, LI Hongjuan, XIANG Yuancui, LIU Huimin. Effect of lncRNA FAL1 on Chemotherapy Resistance of Ovarian Cancer Cells by Regulating MAPK Pathway and Related Mechanism[J]. Cancer Research on Prevention and Treatment, 2021, 48(04): 333-340.
[6] GAO Chang, ZHANG Shuang, WEN Zhaoyan, GONG Tingting, ZHAO Yuhong, WU Qijun. Research Progress on Relation Between Shift Work and Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(03): 293-298.
[7] CHEN Chao, ZHAO Yamei, GE Xiaoxu, WANG Jian, WANG Da, DING Kefeng, SUN Lifeng. Current Status and Challenges of Treatment on Colorectal Cancer Peritoneal Metastasis with Ovarian Metastasis[J]. Cancer Research on Prevention and Treatment, 2020, 47(12): 915-918.
[8] ZHANG Lixuan, LIU Chaoqi, LI Zhiying. Research Progress of Secreted Frizzled-related Proteins in Female Malignant Tumor[J]. Cancer Research on Prevention and Treatment, 2020, 47(03): 218-222.
[9] WANG Juan, CHEN Youguo, ZHA Xueli, ZHOU Jinhua. Efficacy of 93 Cases of Recurrent Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(01): 58-62.
[10] YANG Jing, WANG Yang, FENG Xiucheng, CAI Hongbing. Adverse Reaction of HIPEC Combined with Intravenous Chemotherapy on Ovarian Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(12): 1131-1135.
[11] ZHANG Xiao, YAN Keqin, FENG Dingqing, LING Bin. Advances in Role of Cyclooxygenase 2 in Development and Progression of Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(11): 1036-1039.
[12] ZHANG Jiayu, HE Xinhui, GONG Tingting, JIANG Yuting, ZHANG Shuang, SUN Hui, WU Qijun. Progress on Relationship of Meat Consumption with Incidence and Prognosis of Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(05): 490-496.
[13] WANG Jia, ZHU Kexiu. Influences of FGF3 and FGF10 on Migration and Invasion of Human Ovarian Cancer SKOV3 Cells and Relation Between These Influences and Wnt/β-catenin Signaling Pathway[J]. Cancer Research on Prevention and Treatment, 2018, 45(12): 970-975.
[14] ZHANG Yunqi, LI Guofeng, SONG Zhihua. Afatinib Sensibilizes Multidrug-resistant Human Ovarian Cancer Cells to Adriamycin and Related Mechanisms[J]. Cancer Research on Prevention and Treatment, 2018, 45(10): 728-734.
[15] LIU Chuanzhong, WANG He, CAI Zhifu, ZHAO Bingbing, LI Li. Prognostic Factors for Different Treatment Regimens in Advanced Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(10): 746-751.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed